PSMC2 Inhibitors
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a clinically approved proteasome inhibitor that targets the 20S proteasome and has been used for multiple myeloma and mantle cell lymphoma. While it does not specifically target PSMC2, it affects the overall proteasome activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib is another proteasome inhibitor investigated for multiple myeloma. It selectively targets the chymotrypsin-like activity of the 20S proteasome and can impact PSMC2 indirectly. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an investigational proteasome inhibitor that targets the 20S proteasome. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that targets the 20S proteasome. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib, also known as CEP-18770, is a proteasome inhibitor that has been evaluated for multiple myeloma and other malignancies. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a natural product proteasome inhibitor that irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome. It has been widely used in research settings to study proteasome function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a peptide aldehyde proteasome inhibitor that reversibly blocks the proteolytic activity of the 20S proteasome. It is commonly used in research to study proteasome-mediated protein degradation. | ||||||